All In Biotech

Free tool

FAERS Monitor: Imcivree

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213793 or its brand name (Imcivree, Setmelanotide Acetate). Reports on generic versions are filed under their own applications.

Reports

285

Serious

187

66% of reports

Hospitalization

106

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea81
  • off label use79
  • skin hyperpigmentation64
  • vomiting43
  • headache42
  • diarrhoea38
  • fatigue36
  • skin discolouration35
  • decreased appetite27
  • melanocytic naevus25
  • weight increased25
  • abdominal pain23
  • injection site pruritus23
  • injection site erythema22
  • injection site pain22

Reports by year received

View as table
YearReports
20201
202122
20229
202332
202433
2025133
202655

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,874 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin hyperpigmentationSignal64553.7445.834,517
melanocytic naevusSignal25423.2290.710,057
skin discolourationSignal3556.241.21,847
injection site pruritusSignal2325.317.1515
injection site erythemaSignal2213.18.8235
decreased appetiteSignal278.66.0175
weight increasedSignal258.25.7153
nauseaSignal817.66.3472
abdominal painSignal237.34.9120
vomitingSignal436.75.1210
off label useSignal796.75.5390
injection site painSignal225.33.573
headacheSignal424.93.7132
diarrhoeaSignal384.33.298
fatigueSignal363.42.561

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.